argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Core Points - The Annual General Meeting of shareholders for argenx SE is scheduled for May 27, 2025, at 13:00 CET in Amsterdam [1] - The formal notice of the meeting, including details on attendance and e-voting, is available on the argenx website [2] - The company's annual report for the financial year ending December 31, 2024, is now accessible on its investor relations page [3] Agenda Items - The agenda includes the discussion and adoption of the 2024 annual accounts, an advisory vote on the 2024 remuneration report, discharge of directors for their 2024 duties, and authorization for the Board to issue shares [4] - It is proposed to re-appoint Anthony Rosenberg as a non-executive director and to adopt a new remuneration policy [4] Company Overview - argenx is a global immunology company focused on severe autoimmune diseases, partnering with academic researchers to develop novel antibody-based medicines [6] - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in various serious autoimmune diseases [6]